Current role
Phil Nickson
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Phil Nickson
The proxy statement of Monte Rosa Therapeutics, Inc. reports total compensation of $1,941,781 for Phil Nickson in fiscal 2025, including a base salary of $520,000. Disclosed compensation is on record for 2 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Monte Rosa Therapeutics, Inc. (GLUE)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Monte Rosa Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Jennifer Champoux COO, Board Member
- Matthew Bowen Chief Accounting Officer
- Andrew Schiff Board Member
- Anthony M. Manning, Ph.D. Board Member
- Anthony Manning Board Member
- Chandra P. Leo Board Member
- Eric A. Hughes, M.D., Ph.D. Board Member
- Filip Janku Board Member
- Jan Skvarka, Ph.D., MBA Board Member
- Philip Nickson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Monte Rosa Therapeutics, Inc. (GLUE) | Chief Business and Legal Officer | $520,000 | $1,941,781 |
| 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Chief Business and Legal Officer | $473,611 | $1,287,628 |
Recent activity
No call appearances or filed executive changes recorded yet.